Table 2.
Aspirin Studies for Prevention of Cardiovascular Events Reporting Information for Diabetic Patients—Patient Characteristics
| Lead Author (Study Acronym), Publication Year | Data Source* | Diabetic Patients n (%)† | Diabetes Type | Cardiovascular History | Prevention Type | Outcomes Reported for Diabetic Patients | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prior MI | Prior Stroke or TIA | Prior CHD | All-Cause Mortality | CV-Related Mortality | MI | Stroke | |||||
| ≤100 mg Aspirin Daily | |||||||||||
| Diener (ESPS-2), 2009 37 | Authors | 479 (15%) | NR | NR | 100% | NR | Secondary | X | X | ||
| Ridker (WHS), 2005 38 | Authors | 1027 (3%) | NR | 0% | 0% | 0% | Primary | X | X | ||
| Elwin (SALT), 1991 39 | Authors | 180 (13%) | NR | 14.4% | 100% | 23.9% | Secondary | X | X | X | X |
| Petersen (AFASAK), 1989 40 | Authors | 59 (9%) | NR | 7.4%‡ | 5.7%‡ | NR | Mixed | X | X | X | |
| Hansson (HOT), 1998 7 | Textbook 52 | 1501 (8%) | NR | 2.5% | 2.5% | 11.1% | Mixed | X | X | X | X |
| Feringa, 2009 48 | Authors | 161 (10%) | NR | 55.0% | 60.0% | 25.0% | Mixed | X | X | X | X |
| Ogawa (JPAD), 2008 11 | Authors | 2539 (100%) | 2 | 0% | 0% | 0% | Primary | X | X | X | X |
| Sacco (PPP-DM Subgroup), 2003 8 | Article | 1031 (22%) | NR | 0% | 0% | 0% | Primary | X | X | X | X |
| Belch (POPADAD), 2008 12 | Article | 1276 (100%) | 1 & 2 | 0% | 0% | 0% | Primary§ | X | X | X | X |
| Catalano (CLIPS), 2007 41 | Authors | 277 (76%) | NR | 3%‡ | 4%‡ | NR | Mixed§ | X | X | X | X |
| Fowkes (AAA), 2010 42 | Authors | 88 (3%) | NR | 0% | 0% | 0% | Primary§ | X | X | X | X |
| McAlister-Low Dose, 2006 49 | Authors | 695 (10%) | NR | 36%‡ | 13%‡ | NR | Mixed | X | |||
| Cubbon-Low Dose,2008 50 | Authors | 273 (11%) | NR | NR | NR | 100% | Secondary | X | |||
| Ong (FDS) Low Dose, 2010 51 | Authors | 405 (100%) | 2 | 3% | 0% | 31% | Mixed | X | X | X | X |
| 101-325 mg Aspirin Daily | |||||||||||
| (PHS), 1989 6 | ADA Statement 16 | 533 (2%) | NR | 0% | 0% | 0% | Primary | X | X | ||
| Farrell (UK-TIA)-Moderate Dose, 1991 43 | Authors | 45 (2%) | NR | 14% | 100% | NR | Secondary | X | X | X | X |
| McAlister-Moderate Dose, 2006 49 | Authors | 1381 (19%) | NR | 36%‡ | 13%‡ | NR | Mixed | X | |||
| Cubbon-Moderate Dose, 2008 50 | Authors | 105 (4%) | NR | NR | NR | 100% | Secondary | X | |||
| Ong (FDS) Moderate Dose, 2010 51 | Authors | 547 (100%) | 2 | 4% | 0% | 41% | Mixed | X | X | X | X |
| >325 mg Aspirin Daily | |||||||||||
| Peto (BMD), 1988 44 | ADA Statement 16 | 101 (2%) | NR | 0% | 0% | 0% | Primary | X | |||
| (ETDRS), 1992 9 | Article | 3711 (100%) | 1 & 2 | 5.5% | 1.5% | 7.7% | Mixed | X | X | X | X |
| Elwood, 1979 45 | Authors | 66 (4%) | NR | 100% | NR | NR | Secondary | X | X | X | X |
| (CDP Research Group), 1976 46 | Authors | 85 (6%) | NR | 100% | 11.9%‡ | NR | Secondary | X | |||
| Farrell (UK-TIA)-High Dose, 1991 43 | Authors | 45 (2%) | NR | 10% | 100% | NR | Secondary | X | X | X | X |
| Cairns, 1985 47 | Authors | 44 (16%) | NR | 40.0%‡ | 2.0%‡ | NR | Secondary║ | X | X | X | X |
| McAlister-High Dose, 2006 49 | Authors | 491 (7%) | NR | 36%‡ | 13%‡ | NR | Mixed | X | |||
| Cubbon-High Dose, 2008 50 | Authors | 39 (2%) | NR | NR | NR | 100% | Secondary | X | |||
| Ong (FDS) High Dose, 2010 51 | Authors | 338 (100%) | 2 | 1% | 0% | 21% | Mixed | X | X | X | X |
*Data source for outcomes in diabetic patients (Authors = authors provided supplemental data not included in original article; Textbook = data obtained from a textbook52; Article = data obtained from original article; ADA Statement = data obtained from the American Diabetes Association position statement on aspirin use for primary prevention in diabetes16)
†Number of diabetic patients and proportion of entire study sample
‡Presence of cardiovascular disease at baseline for entire study sample
§All patients had peripheral arterial disease at baseline
║All patients had unstable angina
MI = Myocardial Infarction; TIA = Transient Ischemic Attack; CHD = Coronary Heart Disease; NR = Not Reported